Once-a-day from Triangle

Published: 2-Mar-2001


Phase III trials have shown Triangle Pharmaceuticals' once daily formulation of emtricitabine (FTC, Coviracil) was well-tolerated and provided antiviral immunologic benefits in the combination treatment of HIV-infected patients. The trials looked at a once-daily regimen that combined emtricitabine wth didanosine and efavirenz. The drug is a nucleoside analogue that is being developed for the treatment of HIV and hepatitis B.

You may also like